发帖
雷达卡
《挑战杯_创业计划书_南京大学昌辉药业》是响应论坛官方悬赏活动第五期中的“全国挑战杯创业大赛计划书”号召，希望版主奖励，谢谢，以下为目录
第一部分 概述
第二部分 公司
1 公司的设立···································· 6
2 公司的宗旨···································· 6
3 发展战略········································ 6
4 企业文化········································ 7
第三部分 产品
1 产品简介········································ 9
2 专利指标········································ 9
3 产品核心技术及主要技术参数········· 10
4 “艾莫迪” 的适应症························ 12
5 “艾莫迪” 的竞争对象····················· 13
6 产品优势········································ 14
6.1 与传统抗肿瘤药物比较········· 14
6.2
与几种竞争对象药物的详细
比较·····································
15
药物用药份额) ·····················
3.6 市场分布(2002 年全国抗肿瘤
药物城市分布) ·····················
31
3.7 市场发展趋势······················· 32
4 抗癌药物市场竞争环境··················· 33
4.1 2002 年单品种通用名购药金
额领先的10种药物···············
33
4.2 主要生产厂家······················· 33
4.3 用药额成长突出的抗肿瘤药··· 34
4.4 进口产品与国产产品的比较··· 35
5 市场总体特点及竞争情况总结········· 35
6 竞争对手分析································· 37
6.1 国内主要竞争对手················ 37
6.2 国外主要竞争者···················· 38
6.3 竞争情况比较······················· 39
6.4 结论····································· 39
7 企业核心竞争力综合分析················ 40
8 市场竞争战略································· 41
9 市场销售额预估····························· 41
第四部分 生产及生产管理
1 产品形式及生产方式······················ 18
2 产品生产········································ 18
3 生产管理········································ 21
4 厂区总体规划································· 22
第五部分 技术研究和开发
1 技术研发战略································· 25
2 公司的研发实力····························· 25
3 研发目标········································ 26
4 具体研发时间预安排······················ 27
第六部分 市场及行业分析
1 抗癌药物发展趋势·························· 29
2 市场调研········································ 39
3 抗癌药物市场总体情况··················· 29
3.1 发病情况······························ 29
3.2 市场总体规模······················· 30
3.3 肺癌发病情况······················· 30
3.4 肺癌药品市场情况················ 30
3.5 用药情况(2002 年各类抗肿瘤 30
第七部分 营销管理
1 目标市场分析································· 45
1.1 目标市场选择······················· 45
1.2 目标市场特征······················· 46
2 营销方案········································ 46
2.1 价格策略······························ 46
2.2 营销渠道······························ 46
2.3 营销方式： 关系营销··············· 47
2.4 营销队伍······························ 50
2.5 营销沟通······························ 50
3 分阶段营销策略····························· 50
3.1 1-2年 市场导入期················ 50
3.2 3-5年 市场成熟期················ 51
3.3 5-12年 市场成熟期··············· 51
3.4 12年以后市场衰退期············ 51
第八部分 财务分析
1 初期资金来源································· 53
2 资金运用········································ 53
3 财务报表········································ 54
4 财务分析········································ 56
4.1 产品方面······························ 56
4.2 经营效率方面······················· 57
4.3 安全性方面·························· 57
4.4 本量利分析·························· 58
4.5 投资报酬分析······················· 58
4.6 敏感性分析·························· 59
5 融资计划········································ 59
6 总结·············································· 61
第九部分 公司管理与人力资源
1 组织形式和治理结构······················ 63
2 组织框架········································ 63
2.1 组织结构设计······················· 63
2.2 各部门职务分析···················· 63
2.3 人员安排策略······················· 64
2.4 各部门人员安排···················· 64
2.5 创业团队组成······················· 65
2.6 产品开发团队······················· 66
2.7 顾问团队组成······················· 67
3 人力资源管理································ 68
3.1 员工引进机制······················· 68
3.2 员工培训机制······················· 68
3.2 员工激励体制······················· 68
第十部分 法律保护
1 药品的各种法律形式比较················ 70
2 具体法律保护策略·························· 70
2.1 技术优势保护······················· 70
2.2 商业优势保护······················· 71
第十一部分 风险分析及应对
1 技术风险及应对····························· 73
2 生产风险及应对····························· 74
3 市场风险及应对····························· 75
4 非市场风险及应对·························· 76
5 资金风险及应对····························· 76
6 法律风险及应对····························· 77
7 结论·············································· 77
附件
1 授权协议书···································· 79
2 市场调研········································ 81
3 技术附件········································ 97
4 财务报表········································ 115
5 访谈记录········································ 128
6 名称涵义········································ 135
7 公司章程········································ 136
8 鸣谢·············································· 142
京公网安备 11010802022788号
